Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation

BACKGROUND: Abiraterone acetate (AA), a selective inhibitor of the CYP17 enzyme, demonstrated a significant improvement in the treatment of patients with metastatic castration-resistant prostate cancer. The risk of endocrine side effects, mainly an increased adrenal mineralocorticoid production, cou...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Prostate Int
Autors principals: Rauch, Simon, Fong, Dominic, Morra, Elisa, Maines, Francesca, Caffo, Orazio, Spizzo, Gilbert
Format: Artigo
Idioma:Inglês
Publicat: Asian Pacific Prostate Society 2016
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4916059/
https://ncbi.nlm.nih.gov/pubmed/27358844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.prnil.2016.02.002
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars